US biotech Enanta Pharma has filed a lawsuit against Pfizer, claiming that its oral antiviral for COVID-19 Paxlovid infringes one of its patents and seeking damages from the pharma giant.

In this article, we are going to take a look at where Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) stands against other best ...

4 analysts have shared their evaluations of Enanta Pharma ENTA during the recent three months, expressing a mix of bullish and bearish perspectives. The table below provides a concise overview of ...

JMP Securities analyst Roy Buchanan reiterated a Buy rating on Enanta Pharmaceuticals (ENTA – Research Report) today and set a price target of $22.00. Roy Buchanan has given his Buy rating due ...

NASDAQ ENTA opened at $11.04 on Thursday. The stock has a market capitalization of $233.82 million, a PE ratio of -1.77 and a beta of 0.58. Enanta Pharmaceuticals has a 1-year low of $8.08 and a 1 ...

Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ) shareholders should be happy to see the share price up 16% in the ...

Cubist Systematic Strategies LLC increased its position in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Free Report) by 65.8% in the 2nd quarter, HoldingsChannel.com reports.

Enanta Pharmaceuticals, Inc. ( NASDAQ:ENTA ) shareholders should be happy to see the share price up 16% in the last... On September 30, 2024, Millennium Management LLC, a prominent hedge fund ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

On Thursday, Enanta Pharmaceuticals (NASDAQ:ENTA) maintained its Buy rating and a price target of $27.00, as endorsed by H.C. Wainwright. The affirmation follows Enanta's announcement of encouraging ...